Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
The study results may prompt doctors to choose vedolizumab over anti-TNF therapy as the first-line treatment for Crohn's disease.
Read Full News1.
Despite Medicare Coverage, Cancer Genomic Testing Still Low
2.
VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets
3.
PRO Data Strengthen Case for Dato-DXd in First-Line TNBC
4.
In a recent study, Kencur ginger's anti-cancer properties were discovered.
5.
Does Telenursing Improve QOL in Breast Cancer?
1.
Spatial Transcriptomics in Oncology: Transforming Tumor Biology and Precision Medicine
2.
Unlocking the Potential of SABCS 2022: Innovative Strategies for Cancer Research
3.
Understanding Mantle Cell Lymphoma Prognosis.
4.
Liquid Biopsy in Hematologic Malignancies: Current Evidence and Clinical Applications
5.
Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Lung Cancer: Risk Factors and Prevention
3.
Efficient Management of First line ALK-rearranged NSCLC - Part III
4.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge